Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.17.20 extracted from

  • Nielsen, V.G.; Kirklin, J.K.
    Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII (2008), Blood Coagul. Fibrinolysis, 19, 793-800.
    View publication on PubMed

Application

Application Comment Organism
medicine argatroban enhances fibrinolysis via a differential inhibition of thrombin-mediated activation of TAFI and factor XIII Homo sapiens

Inhibitors

Inhibitors Comment Organism Structure
additional information argatroban enhances fibrinolysis via a differential inhibition of thrombin-mediated activation of TAFI and factor XIII: Plasma is exposed to argatroban or heparin, with coagulation initiated with kaolin/tissue factor and fibrinolysis initiated with tissue plasminogen activator. Argatroban significantly decreases clot lysis time and increases the maximum rate of lysis compared with unexposed plasma, whereas heparin exposure only diminishs clot lysis time. Experiments with TAFI-deficient and factor XIII-deficient plasma demonstrate a sparing of thrombin-mediated factor XIII activation with concurrent inhibition of TAFI activation Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
plasma
-
Homo sapiens
-

Synonyms

Synonyms Comment Organism
TAFI
-
Homo sapiens
thrombin-activatable fibrinolysis inhibitor
-
Homo sapiens